Proven Results

Fight HCC At Every Stage.

Interventional Oncology / Cancer Therapies & Ablation / TheraSphere / Proven Results


Significant Investments Have Been Made to Advance Clinical Evidence With TheraSphere

The LEGACY Study

Learn how the LEGACY study confirms TheraSphere as a neoadjuvant or standalone therapy in treating HCC.

20 Years of Success in HCC Treatment

Well-tolerated by patients and backed by clinical evidence, TheraSphere has been shown to improve survivability and quality of life in your cancer* patients. It gives you the power to reliably shrink and destroy tumors* at every stage, from extending lives to curative intent.

  • 1999 TheraSphere receives FDA HDE approval
  • 2004 Advanced HCC with or without PVT1
  • 2006 Downstaging and bridging to transplant2
  • 2009 Radiation lobectomy: local tumor shrinkage and hypertrophy of normal liver3
  • 2011 Radiation segmentectomy: high-dose radiation delivered to ≤ 2 hepatic segments4
  • 2014 Radiation segmentectomy threshold dose
    >190 Gy5
  • 2018 Curative intent: early HCC and low tumor burden6
  • 2020 Legacy confirms neoadjuvant or standalone treatment in HCC8,9 Dosisphere-01 personalized dosimetry approach improves overall survival7

Hear From Y-90 Leaders

Key opinion leaders discuss the impact in treating cancer* patient with TheraSphere and practicing in a multiple disciplinary setting.

Dr Tablri-Treating a Wide Range of Patients.
Nora Tabori, MD an Interventional Radiologist at MedStar Washington Hospital touches on the complexities of treating cancer* patients that also have other diseases. “In those patients, we can offer something that's a very durable result and in fact, possibly even curative intent.”
Exceeding the Standards of Care video.
Riad Salem, MD an Interventional Radiologist at Northwestern Memorial Hospital cares about results and treatment tolerability in his patients. “We studied Y-90 in HCC patients at all stages of the disease and we found that it was either equal to or better than the current standards of care but providing a much more gentle treatment for patients. And that was enough to seal the deal.” 
Dr Kim-Functioning in a Multi-Disciplinary Team.
 Edward Kim, MD FSIR, Associate Professor of Radiology and Surgery, Director of Interventional Oncology with Mount Sinai Health Systems shares his experience with TheraSphere and its ability to help his multi-disciplinary teams treat patients with HCC.

Key Clinical Data Shows TheraSphere Improves Overall Survival in Patients Across All Stages of HCC

Every patient is unique and every stage of HCC has its specific challenges. TheraSphere is a versatile, evidence-based cancer* therapy with proven clinical results of breakthrough outcomes.

Bridging & Downstaging to Surgery bar.
Bridging & Downstaging to Surgery ›

Radiation Segmentectomy bar.
Radiation Segmentectomy ›

Radiation Lobectomy bar.
Radiation Lobectomy

LOBAR + PVT bar.

Institutional Decision to Adopt Y-90 as a Primary Treatment for HCC Informed by a 1000-Patient 15-Year Experience

15 year, 1,000 patient cohort treated with TheraSphere show benefits across all stages of cancer.*14


View Clinical Study ›

  1. Salem R, Lewandowski R, Roberts C et al. J Vasc Interv Radiol. 2004; 15(4) 335-45
  2. Kulik LM, Atassi B, van Holsbeeck L et al. J Surg Oncol. 2006;94: 572-586
  3. Gaba RC, Lewandowski RJ, Kulik LM et al. Ann Surg Oncol. 2009 Jun;16(6):1587-96
  4. Riaz A, Gates VL, Atassi B et al. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):163-71
  5. Vouche M, Habib A, Ward TJ et al. Hepatology. 2014;60(1):192-201
  6. Lewandowski RJ, Gabr A, Abouchaleh N et al. Radiology. 2018;287(3) epub
  7. Garin et al, J Clin Oncol 38, 2020 (suppl 4; abstr 516)
  8. 3020.2: Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma: The LEGACY Study,” CIRSE 2020 Virtual Summit, September 12-15, 2020.
  9. Hepatology. 2020 May 16. doi: 10.1002/hep.31318.Online ahead of print. Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort Ahmed Gabr, et al. DOI: 10.1002/hep.31318
  10. Gabr, A., Kulik, L., Mouli, S., Riaz, A., Ali, R., Desai, K., Mora, R.A., Ganger, D., Maddur, H., Flamm, S., Boike, J., Moore, C., Thornburg, B., Alasadi, A., Baker, T., Borja‐Cacho, D., Katariya, N., Ladner, D.P., Caicedo, J.C., Lewandowski, R.J. and Salem, R. (2020), Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐year Experience in 207‐Patient Cohort. Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31318 >=30% hepatic reserve
  11. Lewandowski RJ, Gabr A, Abouchaleh N et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018; 287(3): 1050-1058.
  12. Gaba RC et al. Ann Surg Oncol 2009;16:1587–96
  13. Garin et al, J Clin Oncol 38, 2020 (suppl 4; abstr 516)
  14. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.

*Refers to HCC or associated tumors
**Utilized personalized dosimetry method with >205 Gy to the index lesion while distributing ≤120 Gy to normal liver